Eisai Co., Ltd. (ESAIY)
| Previous close | 11.35 |
| Open | 11.50 |
| Bid | 10.97 x 40000 |
| Ask | 11.00 x 0 |
| Day's range | 10.97 - 11.50 |
| 52-week range | 9.31 - 21.00 |
| Volume | |
| Avg. volume | 115,185 |
| Market cap | 12.659B |
| Beta (5Y monthly) | -0.06 |
| PE ratio (TTM) | 45.71 |
| EPS (TTM) | 0.24 |
| Earnings date | 31 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | 0.26 (2.30%) |
| Ex-dividend date | 27 Mar 2024 |
| 1y target est | N/A |
PR NewswireEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. L
PR NewswireEisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with
Yahoo FinanceAlzheimer's drug Leqembi: The twice-monthly infusion could be available in injection form
An Alzheimer's drug in injectable form could be the key for Biogen, Eisai to ease pressures and concerns of a limited market and revenue.
